101582-69-8Relevant articles and documents
HYPOXIA ACTIVATED DRUGS OF NITROGEN MUSTARD ALKYLATORS
-
, (2009/12/23)
Hypoxia activated drug compounds having a structure of formula(I) are useful in the treatment of cancer and other hyperproliferative diseases.
A higher yielding synthesis of the clinical prodrug ZD2767P using di-protected 4-[N,N-bis(2-hydroxyethyl)amino]phenyl chloroformate
Niculescu-Duvaz, Dan,Scanlon, Ian,Niculescu-Duvaz, Ion,Springer, Caroline J.
, p. 6919 - 6922 (2007/10/03)
A novel synthesis is described of the prodrug ZD2767P (in Phase I/II clinical trials) that improves the overall yield from 13% to 45%. The method involves the synthesis of 4-[N,N-bis(2-hydroxyethyl)amino]phenyl chloroformate protected as the bis-silyl ether, coupled with di-tert-butyl glutamate. There are clear advantages of this method compared to the literature procedure.
Methods of chemical systhesis of phenolic nitrogen mustard prodrugs
-
, (2008/06/13)
This invention pertains to novel methods for the synthesis of certain nitrogen mustard prodrugs, such as N-[4-[N,N-bis(2-haloethylamino)-phenoxycarbonyl]-L-glutamic acid: wherein: X2 is a halo group, and is —F, —Cl, —Br, or —I; n is an integer
Melanocyte-directed enzyme prodrug therapy (MDEPT): Development of second generation prodrugs for targeted treatment of malignant melanoma
Jordan, Allan M.,Khan, Tariq H.,Malkin, Hugh,Osborn, Helen M.I.,Photiou, Andrew,Riley, Patrick A.
, p. 1549 - 1558 (2007/10/03)
Evaluation of second generation prodrugs for MDEPT, by oximetry, has highlighted structural properties that are advantageous and disadvantageous for efficient oxidation using mushroom tyrosinase. In particular, a sterically undemanding prodrug bis-(2-chlo
Melanocyte-directed enzyme prodrug therapy (MDEPT): Development of a targeted treatment for malignant melanoma
Jordan, Allan M.,Khan, Tariq H.,Osborn, Helen M. I.,Photiou, Andrew,Riley, Patrick A.
, p. 1775 - 1780 (2007/10/03)
A novel prodrug rationally designed to function as a tyrosinase substrate has been synthesised to allow targeted treatment of malignant melanoma. This agent has been evaluated for tyrosinase-mediated drug release, and has been shown to act in the desired
Glucuronide prodrugs of hydroxy compounds for antibody directed enzyme prodrug therapy (adept): A phenol nitrogen mustard carbamate
Schmidt,Florent,Monneret,Straub,Czech,Gerken,Bosslet
, p. 1071 - 1076 (2007/10/03)
A prodrug consisting of a β-D-glucuronic acid linked to a self-immolative spacer (a N-(ortho-hydroxyphenyl)-N-methylcarbamate) and a phenolic nitrogen mustard was synthesised. As this prodrug was easily cleaved by a β-glucuronidase enzyme and displayed lo